Design Therapeutics
DSGN
50 hedge funds and large institutions have $546M invested in Design Therapeutics in 2021 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 13 increasing their positions, 6 reducing their positions, and 11 closing their positions.
117% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 6
64% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 11
16% more funds holding
Funds holding: 43 → 50 (+7)
2.18% more ownership
Funds ownership: 47.87% → 50.05% (+2.2%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
28% less capital invested
Capital invested by funds: $755M → $546M (-$209M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$27.3M |
| 2 |
BlackRock
New York
|
+$15.5M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$7.57M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$5.43M |
| 5 |
State Street
Boston,
Massachusetts
|
+$4.75M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$7.57M |
| 2 |
Janus Henderson Group
London,
|
-$6.31M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$5.11M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$3.91M |
| 5 |
Goldman Sachs
New York
|
-$1.57M |
DSGN Hedge Fund Activity: Q2 2021 in Review
50 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Design Therapeutics (DSGN) for Q2 2021, worth a combined $546M — down 28% from $755M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new DSGN positions and 11 closed out — a net gain of 7 holders — while 13 added to existing stakes and 6 trimmed.
The largest buyer was Vanguard Group, adding an estimated $27.3M. The largest seller was Millennium Management, exiting entirely with an estimated $7.57M sold.
- 50 institutional investors held Design Therapeutics (DSGN) as of Q2 2021, up from 43 in Q1 2021.
- Funds reported $546M of Design Therapeutics stock for Q2 2021, down 28% quarter-over-quarter.
- 18 funds opened new Design Therapeutics positions in Q2 2021 and 11 closed out, a net change of +7 holders.
- The largest Design Therapeutics buyer in Q2 2021 was Vanguard Group, an estimated $27.3M added.
- The largest Design Therapeutics seller in Q2 2021 was Millennium Management, an estimated $7.57M sold.
Based on aggregated 13F filings for Q2 2021.